Question

Scenario 3: HK, a 47-year-old WM, presents to the internal medicine resident clinic for management of his type 2 diabetes mellitus and CKD. Unfortunately, HK's SCr has increased from 1.2 mg/dL to 1.6 mg/dL. He is currently only taking Invokana 100 mg PO daily because he experienced intolerable Gl adverse effects from metformin. The resident asks you if HK's Invokana dose can be increased to 300 mg PO daily today for better glycemic control. 7. Based on HK's SCr, what is her eGFR today in mL/min/1.73 m2? You will enter your answer rounded to the nearest whole number in Examsoft - no units. Fill in the blank eGFR: 47 8. What would your recommendation be for the resident regarding HK's Invokana? a. Increase dose to Invokana 300 mg PO daily b. Continue current dose C. Canagliflozin is contraindicated and should be discontinued today d. Increase dose to Invokana 300 mg PO every other day 9. The resident also asks you if HK would be able to start on a GLP-1 receptor agonist today, preferably one that would not require renal dose adjustments. From the answer choices below please select all of the options that would NOT require renal dose adjustments. a. Ozempic b. Adlyxin c. Trulicity d. Victoza

Answer 1

7 50 ml / min 1 173m2 based on so ceod 1. buffet 8. b. contencie cessent dose as dose is lenited to loong once daily in patients a CSFR - of us -<60ml/ men M. 73 m² & It is safe to use in cks poctens. 9. a. Orempic 1 b. Adlynn c. Truelicity d. Victoza le all need no rexed dose adjustment Scanned with CamScanner